Clinical trials: Bone Sarcomas
Sarcoma, Neutropenia
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
Physicians are conducting a clinical trial for patients with pediatric sarcoma. Sarcoma is a type of bone cancer that can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced.
- Trial name
- NCT00035620
- Testing
- pegfilgrastim, filgrastim
- Volunteers
- 44 people
- Sponsor
- Amgen
Solid Tumor, Lymphoma
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with…
- Conditions
- Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma
- Trial name
- NCT05093322
- Testing
- Surufatinib in combination with Gemcitabine
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Hutchmed
Solid Tumor, Ewing Sarcoma
Expanded Access of Vigil in Solid Tumors
This is an expanded access study involving an investigational product named Vigil. Vigil is considered immunotherapy. Patients who participated in another clinical trial sponsored by Gradalis, and had Vigil made from their tumor…
- Conditions
- Solid Tumor, Ewing Sarcoma, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- NCT03842865
- Testing
- Vigil
- Where
- United States
- Sponsor
- Gradalis, Inc.
Ewing Sarcoma, Colorectal Adenocarcinoma
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
- Trial name
- NCT03715933
- Testing
- INBRX-109, Irinotecan, Temozolomide
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 411 people
- Sponsor
- Inhibrx Biosciences, Inc
Neuroblastoma, Ewing's Sarcoma
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
This study will be carried out in children with diagnosis of cancer with tumors known to express N-glycolylated gangliosides. The disease must be resistant to conventional therapy.
- Conditions
- Neuroblastoma, Ewing's Sarcoma, Wilm's Tumor, Retinoblastoma
- Trial name
- NCT01598454
- Testing
- racotumomab
- Where
- Argentina
- Volunteers
- 15 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Refractory Osteosarcoma, Recurrent Osteosarcoma
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma
The purpose of this study, a single-center, open, single-dose clinical study, was to evaluate the safety, tolerability, and pharmacokinetic profile of IM83 CAR-T cells in the treatment of patients with relapsed or refractory…
- Trial name
- NCT06412458
- Testing
- IM83 CAR-T Cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited
Brain and Central Nervous System Tumors, Neuroblastoma
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
The purpose of this study is to test the feasibility and toxicity of administering intrathecal immunotherapy for patients with central nervous system/leptomeningeal (CNS/LM) malignancies.
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Trial name
- NCT00089245
- Testing
- Iodine I 131 MOAB 8H9
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Y-mAbs Therapeutics
Metastatic Soft-Tissue Sarcomas, Metastatic Bone Sarcomas
Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)
The purpose of this study is to determine whether maintenance therapy with oral AP23573 (ridaforolimus), by preventing and controlling tumor growth for a prolonged period of time in patients with metastatic soft-tissue or bone…
- Trial name
- SUCCEED (NCT00538239)
- Testing
- ridaforolimus
- Volunteers
- 711 people
- Sponsor
- Merck Sharp & Dohme LLC
Ewing Sarcoma
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma.
- Trial name
- NCT06564272
- Testing
- KC1036
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.
- Conditions
- Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01474681
- Testing
- HSC835
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Osteosarcoma
Surveillance Study of Patients With Newly Diagnosed Osteosarcoma
This study is an observational safety surveillance study designed to prospectively assess patients with high-grade osteosarcoma who are candidates for treatment with mifamurtide within the context of prevailing standard oncology…
- Trial name
- NCT01194284
- Testing
- Mifamurtide
- Where
- Austria
- Volunteers
- 25 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.
- Trial name
- NCT02748135
- Testing
- TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg
- Where
- 10 sites in United States
- Volunteers
- 18 people
- Sponsor
- Oncurious NV
Sarcoma
Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)
The study evaluates efficacy of Ridaforolimus when administered as maintenance therapy to patients with metastatic bone or soft-tissue sarcoma in Japan.
- Trial name
- NCT01010672
- Testing
- Ridaforolimus
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Ewing's Sarcoma, Ewing Family of Tumors
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
The purpose of this study is to determine the safety and the maximum tolerated dose of of pbi-shRNA™ EWS/FLI1 Type 1 lipoplex in patients with advanced Ewing's sarcoma.
- Conditions
- Ewing's Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- NCT02736565
- Testing
- pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gradalis, Inc.
Neuroblastoma, Osteosarcoma
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).
- Conditions
- Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
- Trial name
- NCT03860207
- Testing
- Humanized 3F8 Bispecific Antibody, Blood draw
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Y-mAbs Therapeutics
Osteosarcoma, Sarcoma, Ewing's
A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)
Participants with relapsed osteosarcoma that can be treated with surgery will be randomized to robatumumab administered intravenously (IV) at one of two dose levels.
- Conditions
- Osteosarcoma, Sarcoma, Ewing's, Peripheral Neuroectodermal Tumor
- Trial name
- NCT00617890
- Testing
- robatumumab
- Volunteers
- 219 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Relapse of Osteosarcoma
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
To establish whether treatment with Inhaled Lipid Cisplatin (ILC) is effective in delaying/preventing pulmonary relapse in osteosarcoma patients in complete surgical remission following one or two prior pulmonary relapses.
- Trial name
- NCT01650090
- Testing
- Inhaled Lipid Cisplatin (ILC)
- Where
- 15 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eleison Pharmaceuticals LLC.
High-Grade Osteosarcoma
Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
This is a multicenter, medical-record-based, retrospective observational study of approximately 400 patients with high-grade osteosarcoma treated at four sites in the Republic of Korea.
- Trial name
- NCT07878364
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- MedPacto, Inc.
Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Expanded Access Program for Selinexor
KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma
- Trial name
- KEAP (NCT07215832)
- Testing
- selinexor
- Sponsor
- Karyopharm Therapeutics Inc